HighMark Wealth Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

HighMark Wealth Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-666	Closed	-$13K	–	570
2022 Q3	$13K	Hold	666	–	–	0.01%	212
2022 Q2	$12K	Hold	666	–	–	0.01%	228
2022 Q1	$11K	Hold	666	–	–	0.01%	257
2021 Q4	$11K	Hold	666	–	–	0.01%	251
2021 Q3	$8K	Hold	666	–	–	0.01%	293
2021 Q2	$9K	Hold	666	–	–	0.01%	280
2021 Q1	$10K	Hold	666	–	–	0.01%	239
2020 Q4	$11K	Hold	666	–	–	0.01%	224
2020 Q3	$8K	Hold	666	–	–	0.01%	262
2020 Q2	$8K	Hold	666	–	–	0.01%	251
2020 Q1	$9K	Hold	666	–	–	0.01%	160
2019 Q4	$3K	Buy	+666	New	+$3.62K	﹤0.01%	337

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

HighMark Wealth Management's KDNY Position: Q4 2022 in Review

HighMark Wealth Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2022, closing a stake of 666 shares — an estimated $13K sold.

HighMark Wealth Management first reported a position in KDNY in Q4 2019 and held it in 12 quarters. The position peaked at $13K in Q3 2022. 155 funds tracked by Wall St. Rank hold KDNY as of Q4 2022.

HighMark Wealth Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
HighMark Wealth Management sold 666 Chinook Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $13K.
HighMark Wealth Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2019 and held it in 12 quarters.
HighMark Wealth Management's Chinook Therapeutics, Inc. Common Stock position peaked at $13K in Q3 2022.
155 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2022.

Based on HighMark Wealth Management's 13F filing for Q4 2022, filed 2 Feb 2023.